An experimental Alzheimer's disease
drug, gantenerumab, may help lower levels of amyloid plaque in the
brains of people with the disease, an early clinical trial indicates. Researchers claims that, of 16 people with mild-to-moderate Alzheimer's disease, those who
received two to seven infusions of the experimental drug every four
weeks showed marked reductions in the amount of plaque in their brains
via imaging tests that were conducted several months after their
treatments.....
More...
